To examine whether signaling through the TGFβ type I receptor is required for tumor sphere formation, we treated cells with SB431542, a selective inhibitor of TGFβ type I receptor kinases that are ALK4, ALK5, and ALK7 [14]. Here, ACVR1B is linked to neoplasm.